Kornimate/medical-research-clean huggingface dataset:
active prevention of upper limb musculoskeletal disorders in thermal environment (muska).

Conditions: Musculoskeletal Disorders

Summary: the main objective of this work is to demonstrate superiority to three months of a standardized short course of spa therapy of 6 days associated with personalized health education program compared to conventional therapy in the management of msds on the functional capabilities of the employees in their daily lives (personal or professional)

musculoskeletal disorders are the leading occupational disease in industrialized countries. the symptoms are varied, their multiple risk factors, work organization may be involved. musculoskeletal disorders affect the muscles, tendons and nerves of the mainly upper limbs (neck, shoulder, elbow, wrist and hand). pain or functional impairment are common to all these disorders.the proposed study is part of an active preventive approach in addressing current employees with latent or symptomatic upper extremity msd linked to a hyper solicitation. this study provide them 6 days spa therapy (before or after work) combined with a health education program to help improve their lives over time.

Eligibility criteria:
inclusion criteria: * tms latent or symptomatic of the upper limbs according to the european consensus saltsa / q score with inrs nordic \> 2 * with or without a history of work stoppage and occupation at the time of inclusion * age: \> 18 years \< 65 years * patient affiliated to a social security scheme ( beneficiary entitled ) * patient has given its consent in writing to participate in the study exclusion criteria: * contraindication to the spa therapy * spa achieved in the last 12 months * trouble behavior or understanding making it impossible to assess

Keywords: upper limb musculoskeletal disorders spa treatment randomized controlled trials education self- management self-care exercise non pharmacological treatment
analysis of hpv and biomarkers present in the biological fluids of patients suffering from head and neck cancer as a non-invasive strategy for detecting recurrence

Conditions: Head and Neck Tumors

Summary: multicenter, non-interventional, retrospective/prospective biological study on patients affected by head and neck tumors, for which the collection and use of tissue samples, blood and saliva for the detection of hpv-dna/rna and mirna.

for each patient they will come collected tissue, blood and saliva samples. in particular, as regards tissue collection, tumor and neighboring tissues will be used healthy specimens taken during surgical removal, according to clinical practice. the fresh tissues thus collected will be stored in rna-later before freezing at - 80°c. furthermore, blood and saliva samples will be taken at different times, in particular: i) the day before surgery; ii) the day after surgery (only for blood); iii) at the time of patient discharge (approximately 15 days after surgery); iii) during the check-up visit scheduled to monitor the patient's follow-up (fu): every 3 months for the first 2 years and every 6 months for the following 3 years. the samples will then be used to carry out nucleic acid extraction, the dna will instead be used to detect the presence of hpv.

Eligibility criteria:
inclusion criteria: * age over 18 years * patients suffering from squamous cell tumors of the oral cavity, pharynx or larynx * surgical patients with hnscc primary tumors, who have not had previous tumors in other sites or adjuvant treatments prior to surgery. * availability of material (tissue) and follow-up data for at least one year (retrospective part) * written informed consent (prospective part/patients in follow-up exclusion criteria: * presence of distant metastases at the time of diagnosis * previous head and neck cancer+ * second cancer under treatment or follow-up for less than 5 years
softened water for eczema prevention pilot trial

Conditions: Atopic Eczema

Summary: an outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study

a 6-month parallel group assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of eczema in neonates, with an embedded mechanistic study. the overall rationale is that by installing a domestic water softener around the time of birth, the infant will be exposed to softened water rather than hard water for bathing and that this will be less irritating to the skin than hard water and so associated with a lower risk of eczema development. the primary objective is to determine the feasibility of conducting a subsequent definitive rct that will investigate whether installation of a domestic water softener around the time of birth can prevent eczema in high-risk babies. the secondary objective is to explore the likely mechanisms by which water softeners might prevent eczema.

Eligibility criteria:
inclusion criteria: * participant (i.e. the neonate) must have a parent or sibling with a history of doctor-diagnosed atopy (i.e. at least one of: eczema, asthma, hayfever) * mother aged ≥18 years of age at enrolment * baby \<36 weeks gestation at screening * informed consent from the mother on behalf of the participant * mother has the ability to understand english * live in a hard water area (\>250 mg/l calcium carbonate) * consent of landlord for installation on water softener (if appropriate) * occupy a property appropriate for installation of a water softener exclusion criteria: * preterm birth (defined as birth prior to 37 weeks gestation) * significant inflammatory skin disease at birth not including seborrheic dermatitis ("cradle cap") * sibling (including twin) previously randomised to this trial. if multiple birth, the first child will be randomised into the trial. * the child is to be fostered/adopted * any immunodeficiency disorder or severe genetic skin disorder * child has any other serious health issue which, at parent or investigator discretion, would make it difficult for the family to take part in the trial. * planned stays away from home for a continuous period of more than 2 weeks or a total of 1 month out of the 6 month follow up period * water softening or filtration device already installed * concurrent enrolment in any other skin-related intervention study * other medical condition that in the opinion of the ci could interfere with the conduct of the trial

Keywords: water hardness atopic eczema prevention skin barrier function skin microbiome
efficacy of dual task training on children with ataxia after medulloblastoma resection

Conditions: Ataxia; Medulloblastoma

Summary: the aim of this study is to evaluate the effect of using a selected dual-task- training program to improve postural stability in children with ataxia after medulloblastoma resection. thirty patients will participate in this study. patients will be classified randomly into two equal groups: study and control groups -both groups will receive conventional physical therapy treatment including mobility exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning. in addition, the study group will receive a selected dual-task training program including balance and cognitive activities. the treatment program will be conducted three days per week for eight successive weeks. the patients will be assessed with the scale of assessment and rating of ataxia, humac balance system, the pediatric balance scale and functional independent measurement. the measures will be recorded two times: before the application of the treatment program (pre) and after the end of the treatment program (post).


Eligibility criteria:
inclusion criteria: all children with the following criteria will be in rolled in the study 1. age range from (5-10 years). 2. severity of ataxia will be from 15-30 by sara scale. 3. children after 2 months of medulloblastoma resection. 4. they can stand and walk with minimal support. 5. they have good cognition, compliance, and ability to understand and instructions. 6. children receiving radiotherapy and chemotherapy sessions 7. they are medically stable exclusion criteria: children will be excluded from the study if they have 1. any neuromuscular disorder. 2. visual impairment. 3. cognitive problem 4. convulsion. 5. peripheral neuropathy due to chemotherapy.
goal-directed and cue-dependent behavior in severe obesity

Conditions: Eating Behavior; Habits; Obesity

Summary: the current proposal aims to investigate implicit and explicit priming paradigms for changing cue-dependent and goal-directed nutritional behavior in participants with severe obesity before and after bariatric surgery as well as in a control group with normal weight.

food choice and intake is a daily and throughout normal subject. however, for more and more people eating habits and the question of food choice are of increasing interest and in several cases even a problem. the prevalence of obesity has tripled in the last decades and it is even spoken of an obesity epidemic. life style interventions to lose weight often fail on the long run, also because people fall back into former unhealthy eating habits. bariatric surgery is a very effective procedure to reduce weight fundamentally. various factors influence our daily food choice, not all of which are apparent to ourselves. thus, food choice might be goal-directed and therefore conscious and reflective, yet in other circumstances the choice to eat something specific might be based on cue dependent processes which are automatic and thus difficult to control. the aim of the current study is to investigate cue-dependent and goal-directed nutritional behavior as well as the effect of a health mindset induction in severe obesity as well as changes in such behaviors due to bariatric surgery.

Eligibility criteria:
inclusion criteria: * experimental: severe obesity * control: normal weight exclusion criteria: * impaired cognitive functions, which might conflict with the task * appropriate german
determination of in vivo ultrafiltration coefficient (kuf) in patients with chronic kidney disease (ckd)

Conditions: Kidney Disease

Summary: the purpose of this study is to determine the in-vivo ultrafiltration coefficient for different sizes of xevonta high-flux dialyzers following fda guidelines.


Eligibility criteria:
inclusion criteria: * written informed consent obtained from patient or parents/ guardian. * subject age \>= 18 * effective blood flow 350 ml/min and dialysate flow of 500 ml/min * on hemodialysis for a minimum of 3 months * use of cimino- or gore-tex shunts * routine dialysis-treatment for 240 min * documented dialysis adequacy parameter that has been stable for past 3 months * plan to dialyze at participating hemodialysis centre for at least 3-months duration. * free from any currently known unusual clotting or access problems * hepatitis b surface antigen (hbsag) negative, documented within the past 90 days or hepatitis b surface antibody (anti-hbs) positive. * anti hepatitis c virus (anti-hcv) negative, documented within the past 90 days * anti human immunodeficiency virus (anti hiv) negative, documented within the past 90 days * hematocrit (hct) between 25 and 40% or haemoglobin (hb) not less than 8 g/dl, as documented 14 days prior to the first treatment exclusion criteria: * patients who are unable to tolerate an effective blood flow of 350 ml/min * patients using catheter for dialysis * pregnant or nursing woman. women of childbearing potential must agree to avoid pregnancy during the study period by use of hormonal contraception (implantable; patch; oral) and/ or double-barrier methods (any double combination of: iud; condom with spermicidal gel; diaphragm; sponge; cervical cap) * previous plan for extended absences from the participating hemodialysis centre * expected to be transplanted (living related donor) within the maximum of 3 months for the study period * any serious medical conditions or disability, which in the opinion of the investigator, would interfere with treatment or assessment or preclude completion of the study

Keywords: in vivo kuf ß2m leptin
combination of buffered anesthetic to treat mandibular molars

Conditions: Symptomatic Irreversible Pulpitis

Summary: the purpose of this study is to determine whether a combination of anesthetics (numbing medicine) will adequately anesthetize teeth over a different combination. a second purpose is to see if the time needed to numb the nerve in a tooth is different between the two anesthetics.

60 human subjects with symptomatic irreversible pulpitis (sip) in mandibular molars will be randomly allocated into 2 groups. one group will receive a combination of: 1 cartridge of buffered 2% lidocaine w/ 1:100k epi via inferior alveolar nerve block (ianb) followed by 1 cartridge of 3% mepivacaine via ianb. this will be followed by 0.5 cartridges (0.9ml) of buffered 4% articaine with 1:100k epi via buccal infiltration and 0.5 cartridges of buffered 4% articaine with 1:100k epi via lingual infiltration. all ianb injections will include a lingual block. the second group will be provided an unbuffered version of the same combination. an electronic pulp tester (ept) will be used to determine the vitality of the treated tooth. endodontic treatment will be initiated after two consecutive ept readings of 80, displaying pulpal anesthesia. profound pulpal anesthesia is described by the patient's report on the visual analog scale after the pulpotomy.

Eligibility criteria:
inclusion criteria: * be between the ages of 18 and 80 years old * have the ability and willingness to independently consent to treatment and study participation * have an uncomplicated medical history (asa i and ii) * not be pregnant * have no allergies local anesthetics/sulfites (confirmed or self-reported) * not be taking any medications that may affect the proper assessment of the anesthetic (no acetaminophen or short-acting nsaids such as ibuprofen within the previous 6 hours; no long-acting nsaids such as naproxen within the previous 16 hours) * not require nitrous oxide during treatment, and the injection area should appear healthy with no other pre-existing conditions or infections that may compromise an accurate collection of data * be experiencing signs of irreversible pulpitis (an exaggerated response to cold that lingers longer than 10 seconds) in a mandibular molar at the time of conducting the study exclusion criteria: * a negative response to cold in the proposed treatment tooth * a radiographic periradicular pathosis more advanced than a widened periodontal ligament or have an intraoral swelling

Keywords: lidocaine articaine mepivacaine buffered local anesthetic irreversible pulpitis
national longitudinal cohort of hematological diseases-large granular lymphocytic leukemia

Conditions: T-LGL Leukemia; NK-LGL Leukemia

Summary: hematological diseases are disorders of the blood and hematopoietic organs. the current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in china. there is a lack of comprehensive and large-scale prospective cohort studies in hematology. the objectives of this study are to investigate the incidence and risk factors of large granular lymphocytic leukemia (lgll) and to analyze the treatment effectiveness, patient prognosis, and healthcare costs in china. 1. analyze the demographic and clinical characteristics of patients with lgll, including sex, age, disease severity, and other relevant factors. 2. examine disease features of lgll patients, such as biochemical and hematological indicators, lgl counts, clonality, bone marrow pathology, and cytogenetics 3. assess treatment patterns and real-world effectiveness in lgll patients. 4. evaluate clinical outcomes, including hematologic response, relapse, and mortality 5. investigate long-term prognosis, including post-discontinuation outcomes and health-related quality of life.


Eligibility criteria:
inclusion criteria: * subjects diagnosed with lgll. * subjects treated at the institute of hematology and blood diseases hospital from jan 1, 2000. exclusion criteria: * subject unlikely to be available for long-term follow-up for any reason (e.g., inability to obtain follow-up data or presence of severe comorbidities). * subject with alcohol or drug dependence that may reduce their compliance with the study. * subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study.

Keywords: treatment patterns hematologic response
effect of fetal ovarian cyst aspiration to prevent torsion

Conditions: Ovarian Cyst; Ultrasonography Prenatal

Summary: the purpose of this study is to determine whether prenatal ovarian cyst aspiration is effective and safe to prevent perinatal ovarian torsion.

with the widespread use of routine sonography during pregnancy, the incidence of fetal ovarian cysts detected in utero has increased in the past decades. however

Eligibility criteria:
inclusion criteria: * pregnant women having an uneventful single pregnancy and a female fetus diagnosed with anechoic ovarian cyst (diameter at least 30mm) exclusion criteria: * multiple pregnancy * complicated pregnancy (pe, diabetes, prom, fetal malformation) * echoic cyst (fluid debris level, septated, retracting clot, globally echoic) * unability to give informed consent

Keywords: aspiration fetal ovarian cyst ovarian torsion
effect of pumpkin seeds on the dietary fatty acid intake and blood pressure in women

Conditions: Cardiovascular Disease; Blood Pressure

Summary: the purpose of this study is to determine if the inclusion of 1.5 ounces of pumpkin seeds per day in the diet of women will alter dietary fatty acid intake or blood pressure.

cardiovascular disease is the number one cause of morbidity and mortality in united states. diets high in polyunsaturated and monounsaturated fatty acids have been shown to decrease the risk of cardiovascular disease. pumpkin seeds are a good source of monounsaturated and polyunsaturated fatty acids. oil extracted from pumpkin seeds has been shown to lower blood pressure. one purpose of this study is to determine whether eating 1.5 ounces of pumpkin seeds per day will improve polyunsaturated and monounsaturated fatty acid intake in the diet in healthy adult women. another purpose of this study is to determine whether eating 1.5 ounces of pumpkin seeds a day will lower blood pressure.

Eligibility criteria:
inclusion criteria: * female * over the age of 18 * able to read, write, and speak english * able to keep a three-day diet diary * willing and able to consume pumpkin seeds exclusion criteria: * pregnant or planning to become pregnant * allergic to pumpkin seeds * high blood pressure * regularly consuming pumpkin seeds (more than 4 times per month) * taking blood pressure medication * liver disease * kidney disease * gastrointestinal disease * history of bariatric surgery * history of a major cardiovascular event * heart disease * currently undergoing cancer treatment (except nonmelanoma cancer) * following a weight control diet * following a disease specific diet * following a vegan diet * have a diagnosed eating disorder

Keywords: dietary fat fat intake blood pressure women phytoestrogen pumpkin seeds cardiovascular disease heart disease secoisolariciresinol monounsaturated fat polyunsaturated fat feeding study
evaluation of two daily disposable contact lenses for wearers with astigmatism

Conditions: Astigmatism; Myopia

Summary: the purpose of this trial is to compare the performance of two contact lenses for contact lens wearers with astigmatism.


Eligibility criteria:
inclusion criteria: * currently wearing soft contact lenses with astigmatism correction * other protocol inclusion criteria may apply exclusion criteria: * eye injury or surgery within twelve weeks prior to enrollment * currently enrolled in an ophthalmic clinical trial * strabismus * any use of medications for which contact lens wear could be contraindicated as determined by the investigator * other protocol exclusion criteria may apply
the clinical trial protocol for the inactivated poliomyelitis vaccine made from sabin strains(sabin ipv)

Conditions: Poliomyelitis

Summary: based on pre-clinical trial and phase 1 and phase 2 clinical data and principle of gcp, the objective of phase ⅲ clinical trial is to evaluate safety and immunogenicity of inactivated poliomyelitis vaccine made from sabin strains(sabin ipv).

the sabin ipv was manufactured with poliovirus type 1, 2, 3 sabin strains and vero cells by microcarrier culture in 550 liter bioreactors. the virus suspension was harvested, ultra-concentrated, purified and inactivated with formalin. the d ag contents of sabin ipv were type 1 30du, type 2 32du, type 3 45du /0.5ml/per dose. inactivated poliomyelitis vaccine (salk strains) was manufactured by sanofi pasteur d ag contents /0.5ml/per dose were type 1 40du, type 2 8du, type 3 32du. this is a randomized, blind phase 3 clinical trial. total 1200 infants (ages 60 days to 90 days) were selected, randomized to two groups (sabin ipv and salk ipv, each group n=600), infants in each group will be vaccinated with three doses of either sabin ipv or salk ipv respectively, one month apart.

Eligibility criteria:
inclusion criteria: * males and females, age from 60 days to 90 days; * adults, parent(s) or guardians are able to understand and sign informed consent for participation; * participants or guardians are able to attend all planned clinical appointment and obey and follow all study instructions; * infants no vaccinated with poliovaccine or other preventive biologicals in recent 7 days; * axillary temperature ≤37℃. exclusion criteria: * have medical record of participants or their family on allergy, convulsion, falling sickness, encephalopathy and psychopathy; * low platelet or bleeding disorder do not allow vaccination into the muscle; * have damaged or lower immunological function; * received blood, plasma or immunoglobulin treatment since birth; * have inborn abnormality, develop obstacles or clinical diagnostic serious chronic ( down syndrome, diabetes, sickle cell anemia or neural guillain-barre syndrome ); * have or be doubtful of following diseases: respiratory system diseases, acute infection or active chronic, cardiovascular diseases, liver and kidney diseases, skin diseases, hiv. exclusion criteria for doses 2 and 3 * have serious anaphylaxis or high fever, convulsion during first dose; * have any circus of exclusion criteria after eligible for study; * have serious adverse event which related to previous vaccination; withdrawal and discontinuance criteria; * received necessary or interference study drugs such as: immune-inhibition or immune-stimulating agents; * vaccinated with any other vaccine（except dtp）; * stop observation determined by investigator owing to occurring serious adverse event.

Keywords: inactivated poliomyelitis vaccine sabin strains poliomyelitis
retrospective review of the cook biodesign® fistula plug to treat anorectal fistulas

Conditions: Anorectal Fistula

Summary: the study is a retrospective review of the use of the biodesign® fistula plug (c-fps-\[x\]). a total of 73 patients will be enrolled who have had a fistula plug placed to treat anorectal fistulas and will therefore be eligible for statistical analysis.


Eligibility criteria:
inclusion criteria: * patients who have had surgery to treat anorectal fistula where the biodesign® fistula plug was placed during the procedure exclusion criteria: * patients not receiving the biodesign® fistula plug for treatment of their anorectal fistula

Keywords: fistula plug